Pretomanid dose selection for pulmonary tuberculosis: An application of multi‐objective optimization to dosage regimen design
Abstract Clinical development of combination chemotherapies for tuberculosis (TB) is complicated by partial or restricted phase II dose‐finding. Barriers include a propensity for drug resistance with monotherapy, practical limits on numbers of treatment arms for component dose combinations, and limi...
Saved in:
Main Author: | Michael A. Lyons (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2021-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pretomanid for tuberculosis treatment: an update for clinical purposes
by: Sara Occhineri, et al.
Published: (2022) -
Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid.
by: Juliano Timm, et al.
Published: (2023) -
Prevalence and genetic basis of Mycobacterium tuberculosis resistance to pretomanid in China
by: Bing Zhao, et al.
Published: (2024) -
ON THE SELECTION OF DRUGS DOSAGE REGIMEN
by: E. N. Bochanova
Published: (2015) -
ON THE SELECTION OF DRUGS DOSAGE REGIMEN
by: E. N. Bochanova
Published: (2015)